Core Insights - SciSparc Ltd. is collaborating with Clearmind Medicine Inc. to develop innovative combination therapies targeting central nervous system disorders and mental health issues [1][3] - A patent application has been published in Mexico for a combination therapy involving MDMA and N-Acylethanolamines, aimed at addressing binge behaviors [2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on cannabinoid pharmaceuticals, with drug development programs targeting Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [4] - Clearmind Medicine Inc. specializes in psychedelic-derived therapeutics, with a focus on addressing alcohol use disorder and other mental health problems [5] Research and Development - The collaboration has resulted in the filing of 13 patents related to the combination therapies in the U.S. and other jurisdictions [3] - Clearmind's intellectual property portfolio includes 19 patent families and 31 granted patents, indicating a strong focus on research and development in the psychedelic space [5]
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico